Physician profile
Thomas Petryk
NPI 1245210244
$808.35
in general payments reported to CMS, 2019-2025
19 companies · $49.67 in 2025
The $49.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2021: $13.23 · 2022: $120 · 2023: $260 · 2024: $119 · 2025: $49.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $113.05 | 2019-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $90.72 | 2022-2025 | Eliquis, Camzyos |
| Abbvie INC. | $74.79 | 2022-2023 | |
| Pfizer INC. | $74.06 | 2023-2024 | |
| Novo Nordisk INC | $72.37 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Sunovion Pharmaceuticals INC. | $53.09 | 2019 | |
| Covis Pharma Gmbh | $48.42 | 2022 | |
| Dexcom, INC. | $44.66 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $43.93 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $38.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.57 | 2019 | |
| Amarin Pharma, INC. | $18.56 | 2019 | |
| Astellas Pharma US INC | $16.92 | 2023 | Veozah |
| Axsome Therapeutics, INC. | $16.42 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $16.32 | 2023 | Dificid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.46 | 2023 | Xarelto |
| Harmony Biosciences LLC | $13.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Petryk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.